IN BRIEF: Scancell Non-Exec Director Diggle Sells 1.3 Million Shares

Fri, 19th Feb 2021 12:40

Scancell Holdings PLC - Oxford, England-based immunotherapies for treatment of cancer and infectious disease - Non-Executive Director Martin Diggle sells 1.3 million shares via Vulpes Life Sciences Fund at average 25.50 pence, worth about GBP318,750, on Wednesday. Vulpes had sold 400,000 shares on Tuesday. Vulpes now has 116.6 million shares, a 14.3% stake.

Current stock price: 25.40p, down 7.6% Friday

Year-to-date change: up 81%

By Tom Waite; thomaslwaite@alliancenews.com

Related Shares

More News

12 Jun 2024 13:13

Shares in Scancell climb as strikes exclusive drug evaluation deal

(Alliance News) - Scancell Holdings PLC on Wednesday announced a major international biotechnology company will exclusively evaluate a Scancell invest...

12 Jun 2024 07:53

Scancell shares jump on new antibody agreement with major biotech firm

(Sharecast News) - Scancell Holdings saw shares surge on Wednesday after the the AIM-listed oncology immunotherapies group announced an agreement with...

26 Mar 2024 14:00

Scancell doses first patient in melanoma-focused trials

(Alliance News) - Scancell Holdings PLC announced on Tuesday that the first patient of a new trial cohort has been dosed with its iSCIB1+ therapeutic....

5 Feb 2024 14:09

TRADING UPDATES: Alliance Pharma appoints chair; FireAngel sales down

(Alliance News) - The following is a round-up of earnings and trading updates by London-listed companies, issued on Monday and not separately reported...

30 Jan 2024 13:56

Scancell interim loss narrows amid finance gain on derivative

(Alliance News) - Scancell Holdings PLC on Tuesday reported a narrowed loss as it gained on the revaluation of derivative liability.